Browsing by Author "Hartmann, Dan"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
Publication First imported case report in Chile of cutaneous leishmaniasis caused by Leishmania infantum(2024) Hartmann, Dan; García, Viviana; Fuentes, Maria; García, Fernanda; Pérez, JaimeLeishmaniasis is a disease caused by a flagellated protozoan of the genus Leishmania. Its clinical presentation and global distribution vary depending on the Leishmania species. There are three classic clinical forms: cutaneous, mucocutaneous, and visceral, the most serious form. In Chile, its not an endemic disease, so a high clinical suspicion must be had. The diagnosis can be confirmed by detection of amastigotes in clinical samples, culture and molecular techniques. There are multiple therapeutic options, both systemic and local. The case of a 60-year-old woman who traveled to Spain and developed cutaneous leishmaniasis due to Leishamnia infantum, being the first case reported in Chile, treated successfully with miltefosine. La leishmaniasis es una enfermedad causada por un protozoo flagelado del género Leishmania. Su presentación clínica y distribución mundial varían dependiendo de las especies de Leishmania. Existen tres formas clínicas clásicas: cutánea, mucocutánea y visceral, la forma más grave. En Chile no es una enfermedad endémica, por lo que se debe tener una alta sospecha clínica. El diagnóstico se puede confirmar por la detección de amastigotes en muestras clínicas, cultivo o técnicas moleculares. Existen múltiples opciones terapéuticas, tanto sistémicas como locales. Se presenta el caso de una mujer de 60 años con antecedentes de un viaje a España y que desarrolló una leishmaniasis cutánea por Leishmania infantum. Es el primer caso de esta especie reportado en Chile, tratado exitosamente con miltefosinaPublication Novel sponge formulation of mesenchymal stem cell secretome and hyaluronic acid: a safe and effective topical therapy for Psoriasis vulgaris(2025) Elgueta, Estefanía; Prieto, Catalina P.; Hartmann, Dan; Carrillo, Daniela; Edwards, Natalie; Martínez, Constanza; Pérez, Dan; Casas, Bárbara; Vergara, Luis; Valenzuela, Fernando; Catalán, Verónica; Lattus, José; Oyarzun-Ampuero, Felipe; Palma, VerónicaBackground Psoriasis vulgaris is the most common form of psoriasis, yet current treatments often lead to significant side effects, resulting in a high rate of therapy desertion. Here, we explored a novel therapeutic approach using the secretome from Wharton Jelly-derived mesenchymal stem cells, biologically stabilized and enhanced with hyaluronic acid (HA), its presentation is an easy-to-apply topical sponge. This formulation had previously demonstrated efficacy in vitro and in experimental psoriasis mouse models. Methods In vitro characterization studies included dynamic light scattering, nanoparticle tracking analysis, optical/electronic microscopy, microbiological experiments, and angiogenic capacity (HUVEC cells). In vivo studies included angiogenic capacity in chicken embryo chorioallantoic membrane (CAM), safety (hypersensitive and healthy volunteers), and efficacy (double-blinded and randomized patients). Results We demonstrated the presence of spherical exosomes (164 ± 87 nm, PDI of 0.38, and 1.5 × 10⁷ particles/mL) within the selected secretomes, which exhibited significant proangiogenic activity in HUVEC cells and in a CAM assay. The secretome-containing sponges displayed distinct physicochemical properties, such as the absence of nitrogen and reduced carbon and oxygen content, resulting in a more cross-linked material with thinner fibers. These characteristics extended the dispersion time in aqueous media. Microbiological testing confirmed sterility in the packed, ready-to-use secretome-HA sponges after 3 months of storage. To assess safety, we selected doses (based on total protein content) that were applied to three patients with atopic dermatitis (42 μg of protein, patch test, 5 days) and four healthy volunteers (210 μg, 15 days) with no observed adverse topical or systemic effects. In a 30-day.